Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study
Ai Cui, Anhui Shi, Lei Deng, Yanyan Sun, Jiayi Yu, Xinrong Lian, Ziyue Zhao · 2026
Read Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study by Ai Cui, Anhui Shi, Lei Deng, Yanyan Sun, Jiayi Yu, Xinrong Lian, Ziyue Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356205.txt.
Description
Ai Cui and colleagues lay out a trial plan, published in 2026, for testing whether a lung-scarring drug can prevent radiation harm in lung cancer care. Patients with advanced lung tumors that cannot be removed often receive combined drug treatment and radiation, and the radiation itself can inflame and scar the lungs. The drug nintedanib already treats one scarring lung disease, so the team asks whether it can also protect these patients.
Under the plan, a small group of patients at three centers in China will be split by chance. Half will take the drug around their radiation course. Half will receive standard care alone. Doctors will track lung injury, safety, and quality of life. Because no results exist yet, the value here is the careful design future findings will rest on.
Catalog record
| CREATOR | Ai Cui, Anhui Shi, Lei Deng, Yanyan Sun, Jiayi Yu, Xinrong Lian, Ziyue Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50979 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |